Featured Studies

Researchers at the National Institutes of Health (NIH) are studying if the medication danazol can be used to treat people with short telomere disease who also have bone marrow failure, liver, or lung disease. In recent studies, danazol, at high doses, showed a positive influence on telomere length. Additional research is needed to learn more about the role of different doses of danazol on telomere disease as well as its effects on secondary diseases.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Women diagnosed with polycystic ovary syndrome (PCOS) needed for a research study at the National Institutes of Health (NIH). Researchers want to learn more about how a medication may be used to help your body's insulin work better and if this can improve your overall metabolic health.

Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins. Researchers want to learn more about the stages of multiple sclerosis and follow them until a person's death to understand how the physical and clinical signs of MS relate to its changes over time.

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

Fanconi anemia is a rare genetic disorder that mostly affects children and often leads to bone marrow failure. Researchers at the National Institutes of Health (NIH) are investigating a new drug to improve blood counts in individuals diagnosed with Fanconi anemia. Eltrombopag is an oral drug that mimics a special protein that causes the body to make more platelets. Currently eltrombopag is used to treat low platelet counts in patients with hepatitis C and chronic immune thrombocytopenic purpura (ITP). Researchers are evaluating if this new drug will improve blood cell counts in individuals diagnosed with Fanconi anemia.

Researchers at the National Institutes of Health seek volunteers, 21-60 years old, to participate in a study researching if a gene and smoking affect drinking. All study-related tests and procedures are provided at no cost to the study participant. Compensation may be provided.

Treatment of severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) usually involves a bone marrow transplant. Researchers at the National Institutes of Health (NIH) are testing ways to make transplant using unrelated donor cells from umbilical cord blood safer and more effective. We hope these procedures will reduce post-transplant complications and improve transplant outcomes.

Researchers at the National Institutes of Health (NIH) Clinical Center seek healthy volunteers for a research study on opioid use disorder (OUD). The purpose of this research study is to learn how opiate use disorder affects dopamine signaling in the brain of people dependent on opioids.